Aug 07, 2018
Daniel Patrick discusses the small biotech company journey from an incubator of ideas to the ability to shepherd an R&D asset through its pipeline to achieving commercial success.
Jul 18, 2018
The Pfizer restructuring will be a case study in whether corporate restructuring & innovation can co-exist or whether M&A is the more viable answer, writes Edward Pratesi.
Jul 18, 2018
Alison Horstmeyer discusses how pharma executives can apply four attributes of curiosity to negotiate VUCA (volatile, uncertain, complex, and ambiguous) conditions and improve organizational outcomes.
Jul 13, 2018
Pharmaceutical Executive
Outlining a real-world case study in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Jul 08, 2018
Pharmaceutical Executive
Kevin J. Slatkavitz discusses how navigating compliance risks requires so much more than policies and procedures.
Jun 22, 2018
Josh Reisberg outlines the foundation of a broad defense strategy for generic companies embroiled in Hatch-Waxman litigations.
Jun 07, 2018
If companies are serious about building a sustainable organization for their employees and becoming a partner to key accounts, they need to be prepared to remodel their whole business around it, writes Miranda Wheatley Price.
May 23, 2018
Pharmaceutical Executive
With so much information readily available companies have lost a significant level of control over how and when details about their progress in drug development and planning related to approval, launch, and commercialization are disseminated.
May 14, 2018
Ellen Coleman outlines the highlights of a recent webinar on ensuring that patient advocacy is a key element of a market access strategy.
Apr 07, 2018
Pharmaceutical Executive
The role of the medical affairs professional in the biopharma hierarchy has grown considerably, but challenges remain in its ascent to true strategic partner with the C-suite, writes Lisa Henderson.
lorem ipsum